Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc, a life sciences company specializing in targeted oncology drugs and diagnostics, is set to reveal its audited preliminary results for the year 2023 on April 30, 2024. The announcement will be accompanied by a live presentation accessible to all shareholders through the Investor Meet Company platform, where attendees can engage with Avacta’s top executives. The company’s ongoing clinical trials have shown promising improvements in the safety and efficacy of cancer treatments, signaling potential growth and advancements in healthcare solutions.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
